Dr Micheal Hedenus of the Haematology Unit of the Sundsval Hospital in Sweden will present promising results on a study on a single iron dose for fatigue treatment in iron deficient women at the 17th Congress of the European Hematology Association in Amsterdam.
Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.000 mg iron dose as ferric carboxymaltose (FCM, Ferinject®, Vifor Pharma, Switzerland) on fatigue symptoms in 294 non-anaemic, iron-deficient but otherwise healthy women with moderate-to-severe fatigue (Piper Fatigue Scale total score ≥5). Fatigue symptoms were assessed before and 7, 28, and 56 days after treatment. The fatigue score improved significantly more often in FCM- than placebo-treated patients.